Capitainer appoints DBS pioneer Donald H. Chace to spearhead US market entry for its next generation dried blood sampling technology
Stockholm, Sweden January 25, 2022 – Swedish medtech Capitainer today announced that Dr Donald H. Chace has been appointed as Capitainer representative for North Americas. Bringing a wealth of experience covering Neonatology, Clinical Chemistry, Newborn Screening, Mass Spectrometry and Forensic Science, he joins the team as Capitainer looks to penetrate the US market with their proprietary qDBS dried blood sampling technology.
Dr Chace is also a longstanding advocate of DBS testing being of one of the primary developers of the newborn metabolic screening test known as Tandem Mass Spectrometry of Amino Acids and Acylcarnitines. This clinical screening test using dried blood spots and including PKU and MCAD deficiency, is used to screen millions of infants per year, worldwide. He has also looked at further developing this method to provide personalized nutritional guidance for infants. Chace has published 100 peer reviewed articles and has presented at numerous conferences that focus on areas in Neonatology, Clinical Chemistry, Newborn Screening, Mass Spectrometry and Forensic Science
“As soon as I got one of the Capitainer cards in my hands I was onboard,” reveals Chace. “The unparalleled precision it delivers heralds the breakthrough we have been waiting and promises to revolutionize healthcare. Now we can at last have a true alternative to liquid blood for diagnostics. This brings a whole range of advantages – from enabling self-sampling of clinical-grade samples to being more straightforward to use in mass spectrometry. I now look forward to setting up evaluations at leading centers across the US for newborn screening and the host of other exciting applications that the Capitainer qDBS card offers.”
“We are delighted to welcome Donald to the team as Capitainer looks to capitalize on the growing interest from US in our DBS technology,” says Christopher Aulin, CEO of Capitainer. “He brings deep knowledge and experience of both mass spectrometry and DBS testing, combined with a strong network of contacts. Above all his enthusiasm for the product is evident and I am confident he will help us make this important next step in Capitainer’s growth.”
About home sampling with qDBS
Capitainer's product qDBS is based on Dried Blood Spot (DBS) technology and is developed by researchers in nanotechnology at Royal Institute of Technology (KTH) in collaboration with researchers from Karolinska Institute. Unlike other DBS-based solutions, qDBS ensures an accurate amount of blood, providing more reliable analytical results and enabling more applications. The sampling card can be transported to a laboratory by regular mail without the need for refrigeration or special packaging.
Contacts
Christopher Aulin, CEO t: +46 708 977 577 e:aulin@capitainer.se
Media
Richard Hayhurst/Ola Bjorkman
Notes to editors
Capitainer AB is a Swedish Medtech company founded in 2013 by Professor Olof Beck from the Department of Clinical Pharmacology at the Karolinska Institute and Professors Göran Stemme, Asso. Prof. Niclas Roxhed and PhD Gabriel Lenk from the division of Micro- and Nanosystems at the Royal Institute of Technology (KTH), Sweden and business consultant Peter Bräutigam.
Capitainer is a supplier of intelligent solutions for Dried Blood and Plasma Spot sampling serving several market segments, including but not limited, to Therapeutic Drug Monitoring, Drug Development and Drugs of Abuse and Alcohol testing. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for healthcare sampling and patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.
For more information visit www.capitainer.se
Tags:
